Citadel Advisors
OACC

Citadel Advisors’s Oaktree Acquisition Corp III Life Sciences OACC Stock Holding History

Citadel Advisors’s Portfolio OACC Stock Details OACC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$109K Buy
+10,253
New +$109K ﹤0.01% 11931
2025
Q2 		– Sell
-14,904
Closed -$152K – 15676
2025
Q1 		$152K Buy
+14,904
New +$150K ﹤0.01% 10855

Other funds holding OACC

AA
AQR Arbitrage Greenwich, Connecticut $6.09B AUM 27.01% 1-Year Est. Return
DAM
Decagon Asset Management London, United Kingdom $386M AUM 45.42% 1-Year Est. Return
FBCM
Fort Baker Capital Management Larkspur, California $1.27B AUM 25.46% 1-Year Est. Return
ECP
Empyrean Capital Partners Los Angeles, California $3.07B AUM 34.24% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
BGIM
Boussard & Gavaudan Investment Management London, United Kingdom $1.06B AUM 4.58% 1-Year Est. Return
LA
Linden Advisors New York $17.9B AUM 1.72% 1-Year Est. Return
SC
Sculptor Capital New York $9.61B AUM 27.49% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
MCM
Moore Capital Management New York $4.92B AUM 35.41% 1-Year Est. Return

Citadel Advisors's OACC Position: Q1 2026 in Review

Citadel Advisors opened a new position in Oaktree Acquisition Corp III Life Sciences (OACC) in Q1 2026: 10,253 shares worth $109K. The stake represents ﹤0.01% of the portfolio and ranks #11931 among its holdings. This is a return to the name: Citadel Advisors previously reported a position in OACC as recently as Q1 2025.

Citadel Advisors first reported a position in OACC in Q1 2025 and has held it in 2 quarters since. The position peaked at $152K in Q1 2025. 51 funds tracked by Wall St. Rank hold OACC as of Q1 2026.

  • Citadel Advisors held 10,253 shares of Oaktree Acquisition Corp III Life Sciences worth $109K as of Q1 2026.
  • Oaktree Acquisition Corp III Life Sciences was a new Citadel Advisors position in Q1 2026.
  • Oaktree Acquisition Corp III Life Sciences made up ﹤0.01% of Citadel Advisors's portfolio in Q1 2026, its #11931 holding.
  • Citadel Advisors first reported a position in Oaktree Acquisition Corp III Life Sciences in Q1 2025 and has held it in 2 quarters since.
  • Citadel Advisors's Oaktree Acquisition Corp III Life Sciences position peaked at $152K in Q1 2025.
  • 51 funds tracked by Wall St. Rank held Oaktree Acquisition Corp III Life Sciences as of Q1 2026.

Based on Citadel Advisors's 13F filing for Q1 2026, filed 15 May 2026.